Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has devastated mankind. To date, no approved treatment is available to completely combat this disease. Although many studies reported the potential of silver nanoparticles’ (AgNPs) action...

Full description

Bibliographic Details
Published in:Heliyon
Main Authors: Laura Wieler, Oana Vittos, Nirmalya Mukherjee, Subhasish Sarkar
Format: Article
Language:English
Published: Elsevier 2023-03-01
Subjects:
COVID-19
Silver nanoparticles
AgNPs
Severe pneumonia
Mortality
Supplemental oxygenation
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023016262
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has devastated mankind. To date, no approved treatment is available to completely combat this disease. Although many studies reported the potential of silver nanoparticles’ (AgNPs) action mechanism and effect against SARS-CoV-2, this is the first clinical trial that aimed to prove this effect. This open-label, randomized, parallel-group, investigator-initiated study (IIS) was conducted in India from 2021 to 2022 and included 40 patients diagnosed with moderately-severe to severe COVID-19 pneumonia. This study proved a significantly higher survival rates (p < 0.05) and significantly lower number of days until supplemental oxygenation was required (p < 0.0001) for patients receiving intravenous AgNPs in form of AgSept® in addition to the standard COVID-19 treatment. This study highlights the importance of intravenous AgNPs administration in the treatment of virus-induced pneumonia.
ISSN:2405-8440

Similar Items